Ketamine-Opioid System Interactions: Naltrexone Studies and Debate

Ketamine-opioid system interactions describe how ketamine, a dissociative anesthetic used off-label at sub-anesthetic doses for treatment-resistant depression, also binds opioid receptors even though its primary mechanism is NMDA receptor antagonism. NMDA receptors are glutamate receptors that ketamine blocks to trigger downstream neuroplasticity, the process most often credited with its rapid antidepressant effect. Opioid receptors are the same receptor family targeted by morphine, buprenorphine, and naltrexone.

A 2018 study found that naltrexone, an opioid receptor antagonist, blunted ketamine's antidepressant response in a small clinical trial, raising the question of whether opioid signaling is required for ketamine to work rather than incidental to it. The finding sparked a debate that has not been resolved. This article reviews ketamine's opioid receptor pharmacology, the naltrexone blockade study and its critiques, and what the unresolved mechanism debate means for patients taking opioid medications alongside ketamine treatment.

Ketamine's Opioid Receptor Pharmacology

Mu-Opioid Receptor Binding

In vitro binding studies show that ketamine and its metabolites bind mu-opioid receptors, though with far lower affinity than NMDA receptors. Racemic ketamine's Ki value at the mu receptor falls between 25 and 50 microM, roughly 50 to 100 times weaker than its NMDA receptor affinity (Hirota et al., 1999). At the plasma concentrations reached during a standard 0.5 mg/kg IV infusion, about 150-300 ng/mL or 0.5-1.2 microM, direct mu receptor occupancy from the parent compound alone is estimated to be modest, based on receptor binding data catalogued in PubChem's ketamine compound summary.

Esketamine, the S-enantiomer, shows roughly twice the mu receptor affinity of arketamine, the R-enantiomer, tracking its greater NMDA receptor potency (Bonaventura et al., 2021). The ketamine metabolite (2R,6R)-hydroxynorketamine has also been reported to interact with opioid receptors, though its binding characteristics and functional effects are not fully mapped.

Kappa-Opioid Receptor Involvement

Kappa-opioid receptors may matter more to ketamine's antidepressant mechanism than mu receptors do. The kappa receptor is activated by the endogenous peptide dynorphin, and dynorphin-kappa signaling is linked to depression, stress response, and dysphoria (Bruchas et al., 2010). Kappa receptor antagonists produce antidepressant-like effects in animal models, and several are in clinical development for depression. If ketamine dampens kappa receptor signaling, directly or by altering dynorphin release, that could add to its antidepressant effect independently of NMDA blockade.

Indirect Effects on the Endogenous Opioid System

Ketamine may also affect the opioid system indirectly through glutamate signaling. NMDA receptor activity regulates release of endogenous opioid peptides such as beta-endorphin, enkephalins, and dynorphins, while opioid receptor activity in turn modulates glutamate release and NMDA receptor function. Blocking NMDA receptors could shift these dynamics in ways that contribute to ketamine's clinical effects (Bhatt et al., 2017).

The Naltrexone Blockade Study That Started the Debate

Williams et al. (2018): Design and Results

Researchers at Stanford University, led by Williams and colleagues, published a study in The American Journal of Psychiatry using a within-subject crossover design. Twelve adults with treatment-resistant depression, a condition described in more detail by the National Institute of Mental Health, received two ketamine infusions of 0.5 mg/kg IV over 40 minutes, at least two weeks apart. One infusion was preceded by oral naltrexone (50 mg, given about two hours before), and the other by placebo.

Naltrexone pretreatment significantly attenuated ketamine's antidepressant effect and also reduced ketamine-induced dissociative symptoms measured by the Clinician-Administered Dissociative States Scale.

What the Findings Suggested

The authors interpreted the result as evidence that opioid receptor activation is a necessary part of ketamine's antidepressant mechanism. If confirmed, that conclusion would revise the NMDA-centric model of how ketamine works, raise questions about abuse potential and dependence liability, and could complicate how ketamine-based treatments are prescribed for patients on opioid-related medications.

Subsequent Studies and Evolving Evidence

A Missing Replication

No larger, multi-site replication of the naltrexone blockade study has been published. Commentators have called for a trial with concurrent pharmacokinetic sampling and a naltrexone-only control arm, but the ethical and practical difficulty of deliberately blunting a potentially life-saving treatment in suicidally depressed patients makes that study hard to run.

PET Imaging and the Buprenorphine Comparison

Bonaventura and colleagues (2021), publishing in Molecular Psychiatry, used PET imaging with opioid receptor radioligands to measure mu-opioid receptor occupancy during sub-anesthetic ketamine infusion in non-human primates. They found measurable occupancy at clinically relevant plasma concentrations, direct evidence that ketamine engages the opioid system in vivo. Receptor occupancy does not automatically mean functional activation, though, so the link between occupancy and antidepressant mechanism is still inferential. Buprenorphine's demonstrated antidepressant efficacy in treatment-resistant depression (Fava et al., 2016) supports the broader idea that opioid modulation can affect mood, but its mechanism differs from ketamine's, so parallel opioid involvement in two separate treatments does not prove opioid receptors drive ketamine's specific effect.

What This Means for Patients on Opioid Medications

The mechanism debate has practical stakes for anyone receiving ketamine while taking opioid medications, whether full agonists for pain management or medications for opioid use disorder such as buprenorphine, methadone, or naltrexone, a topic covered in more depth in our drug interactions guide. If opioid receptors contribute meaningfully to ketamine's antidepressant mechanism, concurrent opioid antagonist therapy could theoretically reduce antidepressant efficacy, while concurrent opioid agonist therapy could enhance or complicate the response.

Clinical observations on this point are mixed. Some clinicians report adequate ketamine response in patients on buprenorphine maintenance, while others have observed attenuated response in patients taking naltrexone for alcohol use disorder, a combination discussed further in our guide to ketamine and alcohol interaction risks (Marton et al., 2023). These reports are confounded by differences in patient populations and the absence of controlled comparisons, so they should be read as clinical impressions rather than established findings.

Implications for Next-Generation Antidepressants

The opioid mechanism debate also bears on development of (2R,6R)-hydroxynorketamine (HNK) as a standalone antidepressant. If ketamine's effect requires opioid receptor engagement and HNK does not meaningfully engage opioid receptors, HNK might lack a component of ketamine's therapeutic mechanism. If HNK instead works through NMDA-independent, opioid-independent pathways, it could offer similar benefit with less abuse potential. Clinical trial results for HNK, when available, will speak directly to this question.

An Integrative Model

A multi-mechanism model may fit the evidence better than a strict either-or framing. Under this view, ketamine's clinical effect could reflect several receptor-mediated processes acting together: NMDA blockade driving the synaptic plasticity changes linked to its rapid effect, opioid modulation contributing to acute mood elevation, and metabolite activity adding NMDA-independent antidepressant effects. The relative weight of each mechanism may vary by individual and clinical presentation (Abdallah, 2020). This model predicts that naltrexone would only partly attenuate ketamine's antidepressant effect, consistent with what Williams et al. observed, and that patients whose depression responds more to opioid modulation would show greater naltrexone-induced attenuation than others, a hypothesis larger studies could test directly.

The Bottom Line

Whether opioid system interactions meaningfully contribute to ketamine's antidepressant mechanism is still an open question. The Williams et al. (2018) naltrexone finding is real and provocative, but a 12-person sample, unreplicated results, and credible alternative explanations mean it cannot settle the mechanism debate on its own. Larger, well-controlled replication studies with pharmacokinetic sampling and mechanistic imaging are needed to resolve it. Until then, ketamine's antidepressant effect likely involves NMDA receptor blockade as its primary driver, with a possible but unconfirmed opioid contribution that matters most for patients also taking opioid medications. For more background on how researchers evaluate findings like these, see our research and evidence overview.